These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Alemtuzumab and myelodysplasia: a story of love and hate (possible alemtuzumab-induced myelodysplastic changes). Braester A; Akria L; Suriu C; Sonkin V Acta Haematol; 2013; 129(3):185-6. PubMed ID: 23257842 [No Abstract] [Full Text] [Related]
26. Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia. Pitini V; Cascio A; Arrigo C; Altavilla G Br J Haematol; 2012 Jan; 156(1):1. PubMed ID: 21790529 [No Abstract] [Full Text] [Related]
27. NCCN: New directions in chronic lymphocytic leukemia. O'Brien S Cancer Control; 2001; 8(6 Suppl 2):114-7. PubMed ID: 11760553 [No Abstract] [Full Text] [Related]
29. Programmed death protein 1 inhibitors making inroads in multiple cancers. Brower V J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444 [No Abstract] [Full Text] [Related]
33. Monoclonal antibodies: magic bullets with a hefty price tag. Shaughnessy AF BMJ; 2012 Dec; 345():e8346. PubMed ID: 23236036 [No Abstract] [Full Text] [Related]
34. What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory? Byrd JC; Rai KR Semin Oncol; 2000 Aug; 27(4):xii-xv; discussion xv-xvi. PubMed ID: 10950363 [No Abstract] [Full Text] [Related]
35. Preclinical data expected for nucleotide GS 9219. AIDS Patient Care STDS; 2007 Apr; 21(4):289-90. PubMed ID: 17506142 [No Abstract] [Full Text] [Related]
39. Treatment and management of chronic lymphocytic leukemia in the elderly: what the pharmacist clinician should know. Johnson TM Consult Pharm; 2012 Apr; 27(4):274-85. PubMed ID: 22498987 [TBL] [Abstract][Full Text] [Related]